Vital KSK Holdings, Inc. (3151) AI Stock Analysis

• Market Cap: ¥59.57B
• Dividend Yield: 3.4%
• Average Volume (3M): 78.69K
• Price to Earnings (P/E): 8.9
• Beta (1Y): 0.48
• Revenue Growth: 2.35%
• EPS Growth: 1.57%
• Country: JP
• Employees: 3,705
• Sector: Healthcare
• Sector Strength: 57
• Industry: Medical - Distribution
• EPS (TTM): 148.34
• Shares Outstanding: 51,902,977
• 10 Day Avg. Volume: 81,910
• 30 Day Avg. Volume: 78,693
• PEG Ratio: 5.69
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Vital KSK Holdings demonstrates solid financial performance with strong revenue growth and a healthy balance sheet. However, challenges in cash flow consistency and current bearish technical indicators weigh on the overall score. Valuation metrics suggest the stock is attractively priced, offering a good dividend yield, which supports its long-term investment potential.

Vital KSK Holdings, Inc. Business Overview & Revenue Model

Company Description

Vital KSK Holdings, Inc. (3151) is a diversified Japanese company engaged primarily in the healthcare and pharmaceuticals sectors. The company focuses on the development, distribution, and sales of pharmaceutical products and health-related goods. Additionally, it may engage in various other business activities related to health and wellness, aiming to improve quality of life through innovative solutions.

How the Company Makes Money

Vital KSK Holdings, Inc. generates revenue through the sale of pharmaceutical products and health-related goods. Its primary revenue streams include the production and distribution of prescription drugs, over-the-counter medications, and health supplements. The company may also earn income through strategic partnerships and collaborations with other firms in the healthcare sector, as well as through investments in research and development to innovate and expand its product offerings. Additionally, Vital KSK Holdings, Inc. might leverage its distribution network to enhance its market reach and drive sales growth.

Vital KSK Holdings, Inc. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
587.48B	579.77B	577.25B	537.06B	562.53B
	Gross Profit
48.30B	44.96B	43.98B	38.22B	45.25B
	EBIT
5.56B	2.47B	2.94B	-2.26B	3.56B
	EBITDA
12.16B	5.82B	6.07B	939.00M	7.22B
	Net Income Common Stockholders
5.84B	4.83B	4.77B	1.17B	4.64B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
34.71B	19.03B	26.97B	29.78B	33.07B
	Total Assets
317.26B	297.32B	313.03B	311.40B	307.70B
	Total Debt
9.11B	10.25B	11.85B	16.80B	17.62B
	Net Debt
-25.60B	-8.78B	-15.12B	-12.99B	-15.46B
	Total Liabilities
211.32B	197.15B	212.99B	207.49B	210.51B
	Stockholders Equity
104.66B	98.98B	98.96B	102.94B	96.34B
Cash Flow		Free Cash Flow
18.47B	-9.60B	3.35B	-5.23B	-9.83B
	Operating Cash Flow
23.57B	-3.00B	7.49B	-1.39B	-8.32B
	Investing Cash Flow
-1.82B	-1.04B	-2.01B	549.00M	2.21B
	Financing Cash Flow
-5.77B	-4.08B	-8.49B	-2.52B	-3.69B

Vital KSK Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1324.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3151, the sentiment is Positive. The current price of 1324 is above the 20-day moving average (MA) of 1275.10, above the 50-day MA of 1228.19, and above the 200-day MA of 1206.19, indicating a bullish trend. The MACD of 30.74 indicates Positive momentum. The RSI at 58.29 is Neutral, neither overbought nor oversold. The STOCH value of 32.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3151.

Vital KSK Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7458	73 Outperform	¥178.80B	11.14		3.48%	5.44%	60.23%
7451	73 Outperform	¥232.92B	10.55		3.46%	2.47%	2.88%
3151	65 Neutral	¥59.57B	8.93		3.40%	2.35%	1.57%
7455	65 Neutral	¥14.04B	15.86		2.90%	2.91%	-53.00%
Sector *	52 Neutral	$5.35B	3.96	-42.60%	2.86%	17.58%	1.27%

Vital KSK Holdings, Inc. Corporate Events

Vital KSK Holdings Unveils Medium-Term Management Plan 2027

Vital KSK Holdings, Inc. has announced its Medium-Term Management Plan 2027, titled ‘Move on to the Next Stage,’ which outlines the company’s strategic initiatives for the next three years starting from FY2025. This plan is expected to guide the company through its next phase of growth, potentially impacting its operational strategies and market positioning.

Vital KSK Holdings Secures Exclusive License for Iron Deficiency Treatment in Japan

Vital KSK Holdings, Inc. announced that its subsidiary, VITAL-NET, Inc., has entered into an exclusive license agreement with Shield Therapeutics plc for the development and commercialization of ACCRUFeR®, an iron deficiency treatment, in Japan. This strategic move aims to expand Vital KSK’s pharmaceutical offerings in Japan, with plans to build a comprehensive distribution and sales network. The agreement involves upfront and milestone payments, as well as royalties, and is expected to enhance the company’s market position and product value chain.

Vital KSK Holdings Revises Earnings and Dividend Forecasts Upward

Vital KSK Holdings, Inc. has revised its earnings and dividend forecasts for the fiscal year ending March 31, 2025, due to strong performance in its pharmaceutical wholesale business. The company anticipates higher profits attributable to owners of the parent, driven by increased sales and foreign exchange gains, despite some offsetting factors. Additionally, the company has increased its year-end dividend forecast, marking the fourth consecutive year of dividend growth, reflecting its commitment to shareholder returns and achieving its highest annual dividend payment since establishment.

Vital KSK Holdings Announces Change in Largest Shareholder

Vital KSK Holdings, Inc. announced a significant change in its largest shareholder as Suzuhiko Co., Ltd. transferred its shares to MH LLC, making MH LLC the new largest shareholder with a 10.12% voting right. This change, classified as an act equivalent to a tender offer, could impact the company’s market dynamics and stakeholder relationships.

Vital KSK Holdings Reports Third Quarter Financial Results

Vital KSK Holdings, Inc. reported a 2.6% increase in net sales for the nine months ending December 31, 2024, signaling growth compared to the same period in the previous year. Despite the increase in sales, operating profit fell by 4.5%, and ordinary profit decreased by 1.3%. The company’s financial position shows a slight increase in total assets and net assets, with a slight decrease in the equity ratio. The forecast for the full fiscal year anticipates minor changes in net sales and profits, reflecting market stability.